Using CagriSema for Weight Loss: A Practical Patient Guide

CagriSema at a glance:

• Drug class: Combination amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection (combined formulation)
• Typical frequency: once weekly
• Half-life: approximately 7 days for both components
• Receptor target: amylin and GLP-1 receptors

If you're considering CagriSema for weight management, the timeline matters. Most users see meaningful change between months 3 and 6, with the bulk of total benefit accruing through month 12.

How Much Weight Loss to Expect

Phase 2 trials showed mean weight loss around 17% at 32 weeks. REDEFINE phase 3 reported 22.7% weight loss at 68 weeks. The headline number from trials is the average — your result will fall somewhere on the distribution around that average.

For planning purposes:

• Strong responders: top quartile of trial average
• Average responders: at or near the trial average
• Lower responders: bottom quartile (still typically meaningful, but less than the headline)

The Time Course

For CagriSema on a weight-loss trajectory, expect the following pattern:

• Months 1-2 (titration): modest scale change; mostly habit shifts
• Months 2-6: the bulk of weight loss happens here for incretin therapies
• Months 6-12: continued slower progress; first plateaus appear
• Year 2+: maintenance becomes the central question

See our CagriSema timeline page for week-by-week detail.

Adjusting Lifestyle on CagriSema

The medication makes appetite changes easier; it doesn't substitute for them. Users who succeed long-term tend to:

• Eat smaller, more frequent meals (delayed gastric emptying makes large meals uncomfortable)
• Prioritize protein (helps preserve lean mass during weight loss)
• Stay hydrated (reduces nausea and supports kidney function)
• Maintain or increase resistance training (preserves lean mass)

Plateau Management

Most users hit a plateau around month 9-12. Options at that point:

• Confirm dose is at maintenance and no titration steps were skipped
• Reassess diet quality and timing
• Increase resistance training
• Discuss escalation or switching with a clinician

For specific plateau strategies, see our plateau guide.

Stopping and Maintenance

The hardest part of GLP-1 weight loss isn't reaching the goal — it's keeping the weight off. Trial extension data show 60-70% of lost weight returns within a year of stopping. Long-term maintenance usually requires sustained medication use.

If you and your clinician decide to taper, do it gradually and pair with intensified lifestyle support.

Cost Reality Check

Weight loss with CagriSema is a long game. At current pricing, annual cost is meaningful — see our CagriSema cost guide for budget planning.

Bottom Line

CagriSema for weight loss works best for people who treat it as a long-term tool, pair it with structured nutrition, and plan for the maintenance phase from day one.

Frequently Asked Questions

Related Reading

• CagriSema: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• CagriSema Side Effects in 2026: Real Reports, Real Solutions
• What Results Should You Expect from CagriSema? A Practical Guide
• The Real CagriSema Price Tag in 2026 — With and Without Insurance
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.
• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.

Individual results vary. This page is informational and is not personalized medical advice.